Table 2

Reasons for stopping prophylaxis or pre-emptive therapy

Cytomegalovirus prophylaxis/pre-emptive therapy
Study AEBreakthrough infectionGraft lossDeathPatient decisionPhysician/investigator decisionOtherTotal number subjects
Humar et al, 201015 27 (8%)51 (16%)11 (3%)14 (4%)320
Halim et al, 201631 2 (1%)1 (0.5%)201
Reischig et al, 201235 10 (14%)2 (3%)70
Reischig et al, 201536 1 13 (11%)4 (3%)3 (2.5%)119
Padulles et al, 201625 1 (2%)53
Palmer et al, 201027 17 (12.5%)7 (5%)3 (2%)15 (11%)3 (2%)136
Boeckh et al, 201529 44 (24%)35 (19%)20 (11%)184
Kim et al, 201030 1 (1.5%)2 (3%)68
Montejo et al, 201039 3 (9%)34
Perrottet et al, 200941 3 (viremia)65
McGillicuddy et al, 201042 3 (2%)1 (1%)
(2)
130
Park et al, 201249 3 8 (8%)6 (6%)37 (38%)97
Invasive fungal infection prophylaxis
Winston et al, 201417 4
Fluconazole
2 (2%)1 (1%)2 (2%)100 (fluconazole)
200 (total)
Chaftari et al, 201248
Posaconazole
8 (38%)21 (posaconazole)
40 (total)
Huang et al, 201219
Itraconazole
29 (20%)12 (8%)1 (1%)4 (3%)147 (itraconazole)
228 (total)
Park et al, 201649
Fluconazole
2 (2%)3 (3%)3 (3%)89 (fluconazole)
250 (total)
Mitsani et al, 201243 25 (27%)93
Cordonnier et al, 201044 2 (4%)3* (7%)11* (2%)45
NI in the following trials (timepoints not specified)
Nanmoku et al, 201840 100
Chawla et al, 201128 37
Witzke et al, 201233 296
Perrella et al, 201247 43
All patients completed treatment protocol in the following trials
Togashi et al, 201138 22
Takenaka et al, 201245 20
  • 1. One patient moved to another country.

  • 2. No information on breakthrough infections during prophylaxis.

  • 3. 12 patients had dosage reductions.

  • 4. 36 patients were preliminarily stopped due to discharge from hospital.

  • *Time-point not confirmed.

  • AE, adverse event; CMV, cytomegalovirus; IFI, invasive fungal infection; NI, no information (not reported).